UK firm to trial T-cell Covid vaccine that could give longer immunity

Emergex is the brainchild of Professor Thomas Rademacher (UCL Infection & Immunity) and will soon start clinical trials of a second-generation vaccine against Covid-19 vaccine, which will come as an easy-to-administer skin patch that uses T-cells.

Read: Guardian